| Literature DB >> 30679748 |
Almudena Espín-Pérez1, Dennie G A J Hebels2,3, Hannu Kiviranta4, Panu Rantakokko4, Panagiotis Georgiadis5, Maria Botsivali5, Ingvar A Bergdahl6, Domenico Palli7, Florentin Späth6, Anders Johansson6, Marc Chadeau-Hyam8, Soterios A Kyrtopoulos5, Jos C S Kleinjans2, Theo M C M de Kok2.
Abstract
PCBs are classified as xenoestrogens and carcinogens and their health risks may be sex-specific. To identify potential sex-specific responses to PCB-exposure we established gene expression profiles in a population study subdivided into females and males. Gene expression profiles were determined in a study population consisting of 512 subjects from the EnviroGenomarkers project, 217 subjects who developed lymphoma and 295 controls were selected in later life. We ran linear mixed models in order to find associations between gene expression and exposure to PCBs, while correcting for confounders, in particular distribution of white blood cells (WBC), as well as random effects. The analysis was subdivided according to sex and development of lymphoma in later life. The changes in gene expression as a result of exposure to the six studied PCB congeners were sex- and WBC type specific. The relatively large number of genes that are significantly associated with PCB-exposure in the female subpopulation already indicates different biological response mechanisms to PCBs between the two sexes. The interaction analysis between different PCBs and WBCs provides only a small overlap between sexes. In males, cancer-related pathways and in females immune system-related pathways are identified in association with PCBs and WBCs. Future lymphoma cases and controls for both sexes show different responses to the interaction of PCBs with WBCs, suggesting a role of the immune system in PCB-related cancer development.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30679748 PMCID: PMC6346099 DOI: 10.1038/s41598-018-37449-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Stratification of the population for LMM analysis implementing PCB exposure and distribution of WBC, where each step address a different research question. *In addition to LMM implementing PCB exposure and distribution of WBC, LMM implementing PCB exposure alone has been performed.
Figure 2Range of PCB exposure for females (“F”, white boxplot) and males (“M”, grey boxplot). *p-value < 0.05 (Student’s t-test).
Number of transcripts after linear mixed model analysis from the female and male population using only PCB as variable of interest.
| Population | Variable of interest | FDR < 0.05 |
|---|---|---|
| Females | PCB118 | 0 |
| Females | PCB138 | 0 |
| Females | PCB153 | 504 |
| Females | PCB156 | 4824 |
| Females | PCB170 | 3939 |
| Females | PCB180 | 4163 |
| Males | PCB118 | 0 |
| Males | PCB138 | 0 |
| Males | PCB153 | 0 |
| Males | PCB156 | 0 |
| Males | PCB170 | 0 |
| Males | PCB180 | 0 |
Pathways (q-value < 0.05) for interaction between PCBs and WBCs in all females and all males (transcriptomics approach, FDR < 0.05).
| Names | Elements | Cancer related pathways |
|---|---|---|
| Females PCB153 Monocytes Females PCB156 Monocytes Females PCB170 Monocytes | Platelet degranulation | |
| Response to elevated platelet cytosolic Ca2+ | ||
| Platelet activation, signaling and aggregation | ||
| Hemostasis | ||
| Females PCB118 B-cell Females PCB153 B-cell | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | X |
| Females PCB118 B-cell | miR-targeted genes in muscle cell - TarBase | |
| Signaling by Hedgehog | X | |
| HH-Ncore | ||
| Females PCB153 B-cell | Regulation of nuclear SMAD2/3 signaling | X |
| Antiviral mechanism by IFN-stimulated genes | ||
| Inositol Metabolism | ||
| Unfolded Protein Response (UPR) | ||
| tgf beta signaling pathway | X | |
| ISG15 antiviral mechanism | ||
| Females PCB156 Monocytes | mcalpain and friends in cell motility | |
| Females PCB170 Monocytes | Formation of Fibrin Clot (Clotting Cascade) | |
| ADP signalling through P2Y purinoceptor 12 | ||
| Common Pathway of Fibrin Clot Formation | ||
| Males PCB156 B-cell | Retrograde endocannabinoid signaling - Homo sapiens (human) | |
| Males PCB170 B-cell | BDNF signaling pathway | |
| Males PCB180 B-cell | Pathways in cancer - Homo sapiens (human) | X |
| Males PCB153 B-cell | Angiogenesis | X |
| Males PCB156 B-cell | ||
| Males PCB156 B-cell | Ca2 + pathway | |
| Proteoglycans in cancer - Homo sapiens (human) | X | |
| Circadian entrainment - Homo sapiens (human) | ||
| G-protein activation | X | |
| Opioid Signalling | ||
| G Protein Signaling Pathways | X | |
| GABAergic synapse - Homo sapiens (human) | ||
| Signaling by Wnt | X | |
| Morphine addiction - Homo sapiens (human) | ||
| Choline metabolism in cancer - Homo sapiens (human) | X | |
| Rap1 signaling pathway - Homo sapiens (human) | ||
| beta-catenin independent WNT signaling | X | |
| Males PCB170 B-cell | Neural Crest Differentiation | |
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||
| Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human) |
Number of transcripts (FDR < 0.05) after LMM analysis after stratifying into controls and future cases for females and males using the interaction PCBs-WBCs.
| Population | Cell type | PCB | Controls | Overlap | LY Future cases |
|---|---|---|---|---|---|
| Females | B cells | 118 | 0 | 0 | 1055 |
| Females | B cells | 138 | 0 | 0 | 650 |
| Females | B cells | 153 | 0 | 0 | 563 |
| Females | B cells | 156 | 2 | 0 | 48 |
| Females | B cells | 170 | 2 | 0 | 14 |
| Females | B cells | 180 | 2 | 0 | 127 |
| Females | CD8T | 118 | 0 | 0 | 0 |
| Females | CD8T | 138 | 0 | 0 | 1 |
| Females | CD8T | 153 | 0 | 0 | 5 |
| Females | CD8T | 156 | 0 | 0 | 4 |
| Females | CD8T | 170 | 0 | 0 | 4 |
| Females | CD8T | 180 | 0 | 0 | 3 |
| Females | CD4T | 118 | 0 | 0 | 3121 |
| Females | CD4T | 138 | 0 | 0 | 2755 |
| Females | CD4T | 153 | 0 | 0 | 3004 |
| Females | CD4T | 156 | 0 | 0 | 3586 |
| Females | CD4T | 170 | 0 | 0 | 4326 |
| Females | CD4T | 180 | 0 | 0 | 5315 |
| Females | NK | 118 | 0 | 0 | 2 |
| Females | NK | 138 | 0 | 0 | 1 |
| Females | NK | 153 | 0 | 0 | 1 |
| Females | NK | 156 | 0 | 0 | 73 |
| Females | NK | 170 | 0 | 0 | 21 |
| Females | NK | 180 | 0 | 0 | 1 |
| Females | Mono | 118 | 0 | 0 | 723 |
| Females | Mono | 138 | 0 | 0 | 7445 |
| Females | Mono | 153 | 1 | 0 | 8373 |
| Females | Mono | 156 | 1 | 1 | 10120 |
| Females | Mono | 170 | 2 | 0 | 9352 |
| Females | Mono | 180 | 2 | 0 | 7944 |
| Males | B cells | 118 | 0 | 0 | 238 |
| Males | B cells | 138 | 0 | 0 | 195 |
| Males | B cells | 153 | 0 | 0 | 61 |
| Males | B cells | 156 | 0 | 0 | 28 |
| Males | B cells | 170 | 0 | 0 | 24 |
| Males | B cells | 180 | 0 | 0 | 14 |
| Males | CD8T | 118 | 1 | 0 | 0 |
| Males | CD8T | 138 | 1 | 0 | 0 |
| Males | CD8T | 153 | 1 | 0 | 0 |
| Males | CD8T | 156 | 1 | 0 | 0 |
| Males | CD8T | 170 | 1 | 0 | 0 |
| Males | CD8T | 180 | 1 | 0 | 0 |
| Males | CD4T | 118 | 1 | 0 | 0 |
| Males | CD4T | 138 | 0 | 0 | 0 |
| Males | CD4T | 153 | 0 | 0 | 0 |
| Males | CD4T | 156 | 0 | 0 | 0 |
| Males | CD4T | 170 | 26 | 0 | 0 |
| Males | CD4T | 180 | 34 | 0 | 0 |
| Males | NK | 118 | 0 | 0 | 0 |
| Males | NK | 138 | 0 | 0 | 0 |
| Males | NK | 153 | 1099 | 0 | 0 |
| Males | NK | 156 | 1227 | 0 | 1 |
| Males | NK | 170 | 3070 | 0 | 0 |
| Males | NK | 180 | 2621 | 0 | 0 |
| Males | Mono | 118 | 1 | 0 | 1 |
| Males | Mono | 138 | 0 | 0 | 2 |
| Males | Mono | 153 | 0 | 0 | 0 |
| Males | Mono | 156 | 21 | 0 | 0 |
| Males | Mono | 170 | 284 | 0 | 5 |
| Males | Mono | 180 | 182 | 0 | 1 |